New Step toward Determining the Cause of Multiple Sclerosis

    Scientists at the University of Toronto say they have found another clue in understanding the cause of what drives multiple sclerosis (MS).  MS is a disorder in which the immune system attacks the brain. It has no known cause and no cure.

    Normally, immune responses are triggered in lymph nodes and other lymphoid organs to provide protection a virus or pathogen. However, scientists have observed that lymphocytes can sometimes congregate into so-called “tertiary lymphoid tissues (TLTs)” in the brain of MS patients. These structures are similar to lymph nodes, but are found within the brain’s meninges. They often coincide with the appearance of tell-tale brain inflammation associated with progressive MS. But how the TLTs are formed and what keeps them there has been unclear.

    The Toronto researchers, led by Jennifer Gommerman, Ph.D., of the department of immunology, discovered that TLTs were created by the presence of stromal cells, specialized cells that produce an intricate network of fibers. They can effectively create a net which, once formed, become a gathering place for T helper 17 cells (Th17).

    “While T cells are an important part of the body’s ability to ward off infection and disease, in autoimmune disorders, they can mistake healthy tissue for potential threats and respond by lashing out, causing damage. The team observed that this Th17 response resulted in the type of brain tissue inflammation associated with MS,” says Dr. Gommerman.

    Moreover, Th17 cells could also influence how the stromal cells organized. The resulting structure that developed was remarkably similar to normal lymphatic tissue, such as you might find in your tonsils or lymph nodes in your neck.

    According to Dr. Gommerman, this study, which was conducted using animal modeling, doesn’t deliver a definitive answer to what causes MS, but it does appear to be a smoking gun associated with MS pathology. With further research, it may point to potential treatment options, such as targeted Th17 blockers.